Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estrone | Estrone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estriol | Estriol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Equol | Equol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Technetium Tc-99m arcitumomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Technetium Tc-99m arcitumomab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Technetium Tc-99m arcitumomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Panitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ranibizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Canakinumab. |